3-Bromo-4-(trifluoromethoxy)benzonitrile, 95.0%, 1g

(E)-2-Cyano-3-phenyl-but-2-enoic acid ethyl ester, 95.0%, 1g

3-(tert-Butyl)-1-(m-tolyl)-1H-pyrazol-5-amine, 95.0%, 1g

2-oxo-2H-pyran-6-carboxylic acid, 95.0%, 250mg

9-(Dicyanomethylene)fluorene, 3g

1-Methyl-5-(trifluoromethyl)-1H-benzimidazol-2-amine hydrobromide, 95.0%, 250mg

5-Borono-2-chlorobenzoic acid, 95.0%, 100g

4-Morpholinophenylboronic acid (contains varying amounts of anhydride), 98.0%, 25g

1,8-Nonadiene>98.0%(GC)5mL

tert-Butyl (2R,3S)-(-)-6-oxo-2,3-diphenyl-4-morpholinecarboxylate, 98.0%, 2.5g

Microliter syringe GASTIGHT® series 1700 Point type 2, 50 µl, 1705 RN, 1 piece

1-(1-Benzyl-1H-pyrazol-4-yl)-ethanone, 97%, 10g

1-[4-(2-fluorophenoxy)phenyl]methanamine, 95%, 100mg